No Data
Cryofocus Medtech's Subsidiary to Collaborate on Research, Development of Cryoballoon Ablation for Lung Cancer
Kangrun Biotech-B (06922.HK): Signed a research cooperation agreement with the Guangzhou National Laboratory and the First Affiliated Hospital of Guangzhou Medical University.
October 16th, KeLonHui丨Kanglong Biological-B (06922.HK) issued an announcement that its wholly-owned subsidiary Ningbo Shengjie Kang Biological Technology Co., Ltd. ("Ningbo Shengjie Kang") will participate in the establishment and management of a research project in Guangzhou National Laboratory together with the First Affiliated Hospital of Guangzhou Medical University. Ningbo Shengjie Kang and Guangzhou National Laboratory, as well as the First Affiliated Hospital of Guangzhou Medical University, have recently signed a research cooperation agreement ("Research Cooperation Agreement") on the aforementioned project. Guangzhou National Laboratory is a new research institution in the field of respiratory system diseases and prevention, and is the core scientific and technological force in the field of respiratory system diseases. Guangzhou Medical
CRYOFOCUS-B: INTERIM REPORT 2024
Cryofocus Medtech Converts Over 29 Million Unlisted Shares to H Shares
Kangfeng Biotechnology-B (06922.HK) completes the full circulation of H shares.
Grandall September 5th | Kanglong Biosciences-B (06922.HK) announced that approximately 29.342 million shares of non-listed shares have been converted to H shares on September 5, 2024, and the conversion of H shares will be listed on the Hong Kong Stock Exchange at 9 am on September 6, 2024. Participating shareholders must complete the applicable domestic arrangements before they can proceed with the H share trade.
Kangfeng Biotechnology-B (06922) released its interim results, with a shareholder's net loss of 52.171 million yuan, a year-on-year increase of 202.2%.
According to the finance and economics news app, Kang Yong Biotechnology-B (06922) released its performance for the six months ending on June 30, 2024, during which the group achieved revenue ...
